SEC Form 4 · accession 0001225208-18-015267
Edwards Lifesciences Corp · EW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Huimin Wang
Officer — CVP, Japan & Intercontinental
Period of report
Nov 5, 2018
Accepted (ET)
Nov 7, 2018 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001099800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 5, 2018 | M | 3,800 | $42.725 | A | 81,665 | D | |
| Common StockF2 | Nov 5, 2018 | S | 1,321 | $151.9737 | D | 80,344 | D | |
| Common Stock | Nov 5, 2018 | S | 1,500 | $152.60 | D | 78,844 | D | |
| Common StockF3 | Nov 5, 2018 | S | 2,601 | $150.9755 | D | 76,243 | D | |
| Common Stock | Nov 5, 2018 | S | 3,800 | $152.60 | D | 72,443 | D | |
| Common StockF4 | Nov 5, 2018 | S | 9,578 | $149.6616 | D | 62,865 | D | |
| Common StockF5 | Nov 6, 2018 | S | 15,000 | $149.9202 | D | 47,865 | D | |
| Common StockF6 | Nov 7, 2018 | G | 16,641 | $0.00 | D | 31,224 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Acquire) | $42.725 | Nov 5, 2018 | M | 3,800 | D | May 9, 2013 | May 8, 2019 | Common Stock | 3,800 | 11,800 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018.
- F2This transaction was executed in multiple trades at prices ranging from $151.52 to $152.2550. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $150.43 to $151.42. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $149.36 to $150.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $149.28 to $150.20. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- F6This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.